For the treatment of EGFR-expressing K-RAS wild Type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (Irinotecan, 5-fluorouracil, leucovorin) for first line treatment
pCODR Provincial Advisory Group
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Do not reimburse
Bristol-Myers Squibb Canada had requested a voluntary withdrawal of the Cetuximab (Erbitux) for mCRC Submission in anticipation of new clinical information and possible resubmission. As per pCODR Procedures B188.8.131.52 b), the pCODR Provincial Advisory Group has decided to continue the review as a PAG Submission in order to obtain a final recommendation that provinces can act on if needed.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.